Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Depreciation & Amortization (CF) (2016 - 2025)

Moleculin Biotech (MBRX) has 10 years of Depreciation & Amortization (CF) data on record, last reported at $22000.0 in Q3 2025.

  • For Q3 2025, Depreciation & Amortization (CF) fell 29.03% year-over-year to $22000.0; the TTM value through Sep 2025 reached $112000.0, down 12.5%, while the annual FY2024 figure was $126000.0, 0.79% down from the prior year.
  • Depreciation & Amortization (CF) reached $22000.0 in Q3 2025 per MBRX's latest filing, down from $28000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $44000.0 in Q1 2021 and bottomed at $22000.0 in Q3 2025.
  • Average Depreciation & Amortization (CF) over 5 years is $33000.0, with a median of $32000.0 recorded in 2022.
  • Peak YoY movement for Depreciation & Amortization (CF): rose 6.67% in 2024, then decreased 29.03% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $34000.0 in 2021, then dropped by 5.88% to $32000.0 in 2022, then rose by 6.25% to $34000.0 in 2023, then dropped by 8.82% to $31000.0 in 2024, then fell by 29.03% to $22000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $22000.0 in Q3 2025, $28000.0 in Q2 2025, and $31000.0 in Q1 2025.